Literature DB >> 32146508

Insufficient increase in bone mineral density testing rates and pharmacotherapy after hip fracture in Japan.

Shinichi Nakatoh1, Kenji Fujimori2, Junko Tamaki3, Nobukazu Okimoto4, Sumito Ogawa5, Masayuki Iki6.   

Abstract

INTRODUCTION: Only a few large-scale studies have examined the care gap in Japan. The present study aims to examine the care gap for secondary fracture prevention.
MATERIALS AND METHODS: Changes in the rates of bone mineral density testing (test rate) and osteoporosis pharmacotherapy administration (treatment rate) before and after hip and vertebral fracture registration were examined based on medical insurance data from the medical care system for elderly individuals in Hokkaido, Japan, issued from July 2013 to December 2018.
RESULTS: The hip fracture group comprised 18,258 women and 4162 men, whereas the vertebral fracture group comprised 34,907 women and 9958 men. Test rates were 0.2% and 1.4% prior to fracture registration (pre-registration) and 19.9% and 40.5% after fracture registration (post-registration) in the hip and vertebral fracture groups, respectively. Moreover, pre-registration treatment rates were 18.3% and 28.2% and post-registration rates were 32.7% and 61.0% in the hip and vertebral fracture groups, respectively. The vertebral fracture group had a significantly higher post-registration test and treatment rates than the hip fracture group. Moreover, the post-registration test and treatment rates in the hip fracture group tended to increase over the years. Both fracture groups showed a tendency for decreased post-registration test and treatment rates as age increased, with lower rates observed among men.
CONCLUSIONS: Test and treatment rates after hip fracture registration remain lower compared with those after vertebral fracture registration. To bridge the care gap following fractures, medical professionals need better awareness regarding osteoporosis treatment for hip fractures among elderly individuals and males.

Entities:  

Keywords:  Bone mineral density testing; Care gap; Hip fracture; Pharmacotherapy; Vertebral fracture

Mesh:

Substances:

Year:  2020        PMID: 32146508     DOI: 10.1007/s00774-020-01093-2

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  3 in total

Review 1.  [Primary fracture prevention through the Osteoporosis Liaison Service.]

Authors:  Shinichi Nakatoh
Journal:  Clin Calcium       Date:  2017

2.  Post-fracture care gap: a retrospective population-based analysis of Hong Kong from 2009 to 2012.

Authors:  M Y Cheung; A Wh Ho; S H Wong
Journal:  Hong Kong Med J       Date:  2018-11-19       Impact factor: 2.227

3.  Impact of a fracture liaison service on patient management after an osteoporotic fracture: the CHUV FLS.

Authors:  Bérengère Aubry-Rozier; Delphine Stoll; Elena Gonzalez Rodriguez; Didier Hans; Veronique Prudent; Ariane Seuret; Alain Farron; Olivier Lamy
Journal:  Swiss Med Wkly       Date:  2018-01-04       Impact factor: 2.193

  3 in total
  3 in total

1.  Insufficient increase in bone mineral density testing rates and pharmacotherapy after hip and vertebral fracture: analysis of the National Database of Health Insurance Claims and Specific Health Checkups of Japan.

Authors:  Shinichi Nakatoh; Kenji Fujimori; Shigeyuki Ishii; Junko Tamaki; Nobukazu Okimoto; Sumito Ogawa; Masayuki Iki
Journal:  Arch Osteoporos       Date:  2021-09-12       Impact factor: 2.617

2.  Insufficient persistence to pharmacotherapy in Japanese patients with osteoporosis: an analysis of the National Database of Health Insurance Claims and Specific Health Checkups in Japan.

Authors:  Shinichi Nakatoh; Kenji Fujimori; Shigeyuki Ishii; Junko Tamaki; Nobukazu Okimoto; Sumito Ogawa; Masayuki Iki
Journal:  Arch Osteoporos       Date:  2021-09-13       Impact factor: 2.617

3.  Accuracy of the Fracture Risk Assessment Tool for judging pharmacotherapy initiation for primary osteoporosis.

Authors:  Hiroshi Fujimaki; Masamitsu Tomioka; Yuko Kanoshima; Akira Morita; Tetsuya Yamori; Yutaka Inaba
Journal:  J Bone Miner Metab       Date:  2022-08-10       Impact factor: 2.976

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.